VISEN Pharmaceuticals (VISEN PHARMA-B) aktie

VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company's lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia, that is in phase 2 clinical trial; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism, which has completed phase 3 clinical trial. It has strategic collaboration agreements with Shanghai Pharmaceutical, XtalPi, Anke Bio, and the United Family Healthcare. VISEN Pharmaceuticals was incorporated in 2018 and is headquartered in Suzhou, China.